Group Leader, Bioconjugation Chemistry at Abzena
Dr. Nicolas Camper is Group Leader for Bioconjugation Chemistry at Abzena. His group focuses on the design and synthesis of antibody-drug conjugates with different combinations of conjugation technologies, linker designs and payloads for pre-clinical evaluation, helping Abzena’s clients establish Proof of Concept and select Lead Candidates for further development. Prior to his position at Abzena, Nicolas worked for PolyTherics where he was involved in the development of the ThioBridge® disulfide rebridging conjugation technology from the early stage. At PolyTherics, Nicolas led CMC efforts resulting in the manufacturing of the first ThioBridge® ADC.
He holds a PhD from Queen’s University of Belfast, on the synthesis of bisphosphonate conjugates to antibody fragments for applications in oncology. Nicolas has experience in bioconjugation, protein engineering, protein expression in bacterial and mammalian systems as well as synthetic chemistry.
Title: Designing and Developing Next-Generation Antibody-Drug Conjugate Medicines
- Deep industry knowledge can be leveraged to support target product profiling for the development of next-generation Antibody-Drug Conjugates (ADCs).
- Design and developability assessments help select successful next-generation ADCs by identifying the right delivery antibody, linker and payload combination using an integrated approach across a multidisciplinary team.
- Process development and GMP manufacturing capabilities of the highly potent payload, the linker, the antibody and the ADC, reduce the overall time to clinic by integrating multiple work streams to accelerate next-generation ADC production for IND submission